Extrahepatic portal vein thrombosis

Area of Science:

• Gastroenterology
• Hepatology
• Vascular Medicine

Background:

• Noncirrhotic, nontumoral portal vein thrombosis (PVT) is the second most common cause of portal hypertension globally.
• Thrombophilic factors are identified in approximately 60% of PVT patients.
• Acute PVT is often asymptomatic, leading to misdiagnosis until complications like variceal bleeding or portal biliopathy arise.

Purpose of the Study:

• To review the current understanding and management of noncirrhotic, nontumoral portal vein thrombosis.
• To highlight the importance of early anticoagulation in acute PVT.
• To discuss management strategies for PVT complications.

Main Methods:

• Literature review of noncirrhotic, nontumoral portal vein thrombosis.
• Analysis of diagnostic and therapeutic approaches for PVT and its complications.
• Synthesis of current recommendations for anticoagulation and management of variceal bleeding and portal biliopathy.

Main Results:

• Early anticoagulation (within 30 days of symptom onset) is recommended for acute PVT to promote recanalization.
• Anticoagulation in portal cavernoma aims to prevent thrombosis progression and recurrence.
• Management of variceal bleeding in PVT follows cirrhotic patient protocols; ursodeoxycholic acid is proposed for symptomatic portal biliopathy.

Conclusions:

• PVT management requires a multidisciplinary approach, focusing on anticoagulation and addressing complications.
• Endoscopic retrograde cholangiopancreatography is indicated for choledocholithiasis complicating bile duct stenosis in PVT.
• Mortality in PVT patients is low and primarily linked to comorbid conditions, not PVT complications.